

1. Record Nr.	UNINA9910780102003321
Autore	Dunkerley David
Titolo	Changing Europe : identities, nations and citizens / / David Dunkerley. [et al.]
Pubbl/distr/stampa	London : , : Routledge, , 2002
ISBN	1-134-49794-6 1-134-49795-4 0-415-26777-3 1-280-40290-3 0-203-30353-9
Descrizione fisica	x, 187 p
Disciplina	323.6094
Soggetti	Citizenship - European Union countries Nationalism - European Union countries
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Bibliographic Level Mode of Issuance: Monograph
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	chapter 1 Introduction -- chapter Union citizenship in the Maastricht Treaty -- chapter Article F (2) TEU -- chapter Article 8(c) EC -- chapter The Charter of Fundamental Rights -- chapter Post-war Europe -- chapter Categorising nationalism -- chapter European regions and EU policy -- chapter Background -- chapter Further reading -- chapter Global human rights -- chapter 1 Introduction -- chapter The origins of a state system and the beginnings of globalisation -- chapter Illustration 2: Spain.

2. Record Nr.	UNINA9911015964003321
Autore	Reau Nancy S
Titolo	Controversies in Hepatocellular Carcinoma // edited by Nancy S. Reau, Amit G. Singal
Pubbl/distr/stampa	Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2025
ISBN	3-031-90225-4
Edizione	[1st ed. 2025.]
Descrizione fisica	1 online resource (548 pages)
Altri autori (Persone)	SingalAmit G
Disciplina	616.994
Soggetti	Oncology Liver Physiology Drug delivery systems Hepatic Physiology Drug Delivery
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Section 1 - Risk Assessment and Chemoprevention -- Controversy 1 - Should All Patients with Hepatitis B Virus Undergo Hepatocellular Carcinoma Surveillance? -- Controversy 2 - Should Hepatocellular Carcinoma Surveillance Be Restricted to Those with Cirrhosis Among Patients With Hepatitis C? -- Controversy 3 - Should Hepatocellular Carcinoma Surveillance Be Performed in Patients with Noncirrhotic Nonalcoholic Steatohepatitis? -- Controversy 4 -Can Risk Stratification Models Be Used to Identify Patients without Cirrhosis who Might Benefit From Hepatocellular Carcinoma Surveillance? -- Controversy 5 - Should Hepatocellular Carcinoma Surveillance Be Performed Only for Patients with Decompensated Cirrhosis if They Are Listed for Liver Transplantation? -- Controversy 6 - Should Statins and Aspirin Be Used for Hepatocellular Carcinoma Chemoprevention in Patients with Cirrhosis? -- Section 2 - Liver Cancer Surveillance -- Controversy 7 - Should A Randomized Controlled Trial of Hepatocellular Carcinoma in Patients with Cirrhosis Be Performed? -- Controversy 8 - Should Contrast-Enhanced Computed Tomography and/or Magnetic Resonance Imaging Play a Routine Role in Hepatocellular Carcinoma

Surveillance in Patients with Cirrhosis? -- Controversy 9 - Should Biomarkers, Such as Alpha Fetoprotein, Play a Routine Role in Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis? -- Controversy 10 - Should Patients with Hepatitis C Virus Cirrhosis Undergo Hepatocellular Carcinoma Surveillance Indefinitely? -- Controversy 11 - Should Patients with Hepatitis C Virus Cirrhosis Undergo Hepatocellular Carcinoma Surveillance Indefinitely? -- Section 3 - Diagnosis -- Controversy 12 - Should All Liver Lesions in Patients with Cirrhosis Be Characterized and Reported Using Liver Imaging Reporting and Data System Criteria? -- Controversy 13 - Can Imaging Findings of Arterial Enhancement and Washout Still Represent a Benign Liver Lesion? -- Controversy 14 - Should Diagnostic Liver Biopsy Be Performed in Patients with Cirrhosis who Have Characteristic Imaging Features of Hepatocellular Carcinoma? -- Controversy 15 - Is Contrast-Enhanced Ultrasound Sufficiently Accurate to Be Used for Noninvasive Diagnosis of Hepatocellular Carcinoma? -- Section 4 - Prognosis -- Controversy 16 - Should Barcelona Clinic Liver Cancer Staging Be Used as the Preferred Staging System for Hepatocellular Carcinoma? -- Section 5 - Treatment Controversy 17 - Should Resection Be the Preferred Therapeutic Option for Patients Within the Milan Criteria and Compensated Cirrhosis Without Portal Hypertension? -- Controversy 18 - Should Liver Transplantation Be the Preferred Therapeutic Option in Patients with Compensated Cirrhosis and Portal Hypertension? -- Controversy 19 - Should Radiation-Based Therapy Be Considered in All Patients with Hepatocellular Carcinoma? -- Controversy 20 - Should Transarterial Radioembolization be the First-Line Therapy Compared to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma? -- Controversy 21 - Should All Patients Listed for Liver Transplantation Receive Bridging Therapy Before Transplant? -- Controversy 22 - Should Transplant Criteria Be Broadened Beyond United Network for Organ Sharing (UNOS) Downstaging Protocol to Include Larger Tumors? -- Controversy 23 - Should All Tyrosine Kinase Inhibitors Be Considered Equal for First-Line Hepatocellular Carcinoma Treatment? -- Controversy 24 - Should All Patients Be Considered for Locoregional Therapy Before Systemic Therapy? -- Controversy 25 - Should Direct-Acting Antivirals Be Given to Patients with Hepatocellular Carcinoma? -- Controversy 26 - Should Locoregional Therapy Be Given in Combination with Systemic Therapy? -- Controversy 27 - Should Patients with Decompensated Cirrhosis Receive Systemic Therapy? -- Controversy 28 - Would Effectively Downstaging Hepatocellular Carcinoma Allow All Patients to Be Considered for Liver Transplantation? -- Controversy 29 - Should Surgery Be Considered for Hepatocellular Carcinoma if Unable to Be Performed at Presentation? -- Controversy 30 - Should Rapamune (Sirolimus)-Based Immunomodulation Be Given Post Transplant for Those Transplanted for or Found to Have Incidental Hepatocellular -- Controversy 31 - Should Systemic Therapy Be Offered to all Patients Post Transplant for Those Transplanted for or Found to Have Incidental Hepatocellular Carcinoma? -- Controversy 32 - Should Post-Liver Transplantation Surveillance for Hepatocellular Carcinoma (HCC) Stop if There Is no HCC Recurrence After 5 Years?.

Sommario/riassunto

This book is written for clinicians who care for patients with hepatocellular carcinoma (HCC) as well as health services researchers doing work in this area. The Editors and authors cover some of the emerging controversial topics that come up in HCC clinical practice and research. There are over 30 questions ranging from screening and diagnosis to therapeutics and survivorship. Chapters are begin with a controversy and the authors defend or refute the question.

Comprehensive and unique, this book aims to help with management of this patient population.

3. Record Nr.	UNINA9910346804003321
Autore	Mireia Freixa
Titolo	CDf International Congress : proceedings : actes, actas : actes, Barcelona Jun. 2013
Pubbl/distr/stampa	Publicacions i Edicions de la Universitat de Barcelona, 2015 Universitat De Barcelona copyright 2015
Descrizione fisica	1 electronic resource (1204 p.)
Collana	Col·leccio Singularitats
Soggetti	History of art / art & design styles
Lingua di pubblicazione	Spagnolo
Formato	Materiale a stampa
Livello bibliografico	Monografia
Sommario/riassunto	[eng] In 2013 the magazine coupDefouet reached its first decade of existence. As a way of celebrating this, the Art Nouveau European Route - the association of cities and other local institutions for the promotion and diffusion of Art Nouveau heritage that created the magazine - organised a magnificent international congress as a framework for scientific exchange and raising public awareness. The first coupDefouet International Congress on Art Nouveau was held in Barcelona, the city from which coupDefouet is published and one of the undisputable world capitals of Art Nouveau. This volume of the Singularitats series comprises the proceedings of that event. [cat] L'any 2013 va fer deu anys del'aparicio de coupDefouet, la revista de la Ruta Europea del Modernisme, una associacio de municipis i altres entitats locals per a la promocio i la difusio del patrimoni modernista o Art Nouveau. Per commemorar-ho, s'organitza un congres internacional amb l'objectiu de contribuir al coneixement científic i la difusio d'aquest moviment artistic. El primer Congres Internacional

coupDefouet se celebra a Barcelona, la ciutat en que s'edita
coupDefouet i una de les capitals indiscutibles del'Art Nouveau. En
aquest volum de Singularitats s'apleguen les actes d'aquell
esdeveniment.
